Jardiance Vaccine Interaction Profile: What Patients and Clinicians Need to Know

Does Empagliflozin Interact With Vaccines?

Empagliflozin does not impair vaccine-induced immune responses. The drug's mechanism targets SGLT2 receptors in the renal proximal tubule and carries no known immunosuppressive pharmacology. The FDA prescribing information for Jardiance lists no vaccine interactions under Section 7 (Drug Interactions) [1].

This absence of a direct interaction does not mean vaccination timing is irrelevant. Diabetes itself is an independent risk factor for impaired vaccine immunogenicity. A 2016 meta-analysis published in Vaccine found that people with type 2 diabetes mount lower antibody titers to influenza vaccine compared to healthy controls [2]. Clinicians prescribing empagliflozin should treat vaccination status as a separate but equally important priority.

Why SGLT2 Inhibitors Are Not Immunosuppressive

SGLT2 is expressed primarily in the kidney, with minimal expression in immune cells. Empagliflozin's selectivity ratio for SGLT2 over SGLT1 is approximately 2,500:1 [1]. Because it does not bind to lymphocytes, macrophages, or antigen-presenting cells, it does not blunt humoral or cell-mediated immunity.

This contrasts sharply with drugs such as mycophenolate mofetil or high-dose corticosteroids, which suppress T-cell proliferation and can reduce vaccine efficacy by 30 to 50% in transplant recipients [3]. Empagliflozin belongs to an entirely different pharmacological category.

Infection Risk and Its Indirect Effect on Vaccination

Jardiance increases the risk of genital mycotic infections and urinary tract infections by promoting glucosuria. In the EMPA-REG OUTCOME trial (N=7,020), genital mycotic infections occurred in 6.4% of women and 3.1% of men on empagliflozin vs. Approximately 1.8% and 0.4% on placebo [4].

Active infection at the time of vaccination is a reason to defer non-live vaccines briefly in some clinical protocols, though the CDC's General Best Practice Guidelines for Immunization note that mild illness without fever is not a contraindication [5]. If a patient presents for a vaccine appointment with a symptomatic UTI or active genital infection, the clinician should use clinical judgment on timing.

Which Vaccines Do Diabetic Patients on Jardiance Need?

The CDC Advisory Committee on Immunization Practices (ACIP) recommends a specific set of vaccines for adults with diabetes mellitus [5]. Empagliflozin does not alter this list, but the drug's cardiovascular and renal indications mean many patients are older adults with additional comorbidities, making vaccine coverage even more clinically significant.

Influenza Vaccine

Annual influenza vaccination is recommended for all adults with diabetes. The American Diabetes Association's Standards of Medical Care in Diabetes, 2024 states: "People with diabetes should receive influenza vaccine annually" [6]. High-dose or adjuvanted formulations are preferred for adults 65 and older.

Empagliflozin does not reduce influenza vaccine immunogenicity. No randomized data shows blunted seroconversion rates in SGLT2 inhibitor users specifically.

Pneumococcal Vaccines

Adults 19 to 64 years with diabetes who have not previously received a pneumococcal vaccine should receive PCV15 followed by PPSV23, or PCV20 alone, per the 2023 ACIP pneumococcal vaccination recommendations [7]. Adults 65 and older follow the standard age-based schedule.

Pneumococcal disease risk is elevated in diabetes because of impaired neutrophil function and complement activation. A 2012 cohort study in Diabetologia (N=124,503) found that people with type 2 diabetes had a 1.5-fold higher risk of invasive pneumococcal disease compared to non-diabetic adults [8].

COVID-19 and Respiratory Syncytial Virus (RSV) Vaccines

Updated COVID-19 vaccines are recommended annually for most adults. RSV vaccination (Abrysvo or Mresvia) is recommended for adults 60 and older, with shared clinical decision-making for adults 50 to 59 who are at elevated risk. Cardiovascular disease and chronic kidney disease, both common in patients on empagliflozin for its approved indications, qualify as elevated-risk conditions [5].

Hepatitis B and Zoster Vaccines

Hepatitis B vaccine (Heplisav-B, two-dose series; or Engerix-B/Recombivax HB, three-dose series) is recommended for all unvaccinated adults through age 59, and for adults 60 and older based on clinical judgment or patient preference [5]. The ADA 2024 Standards specifically list hepatitis B among recommended vaccines for people with diabetes [6].

Recombinant zoster vaccine (Shingrix, two doses) is recommended for adults 50 and older regardless of prior zoster history. Immunocompromised adults 19 and older also qualify. Jardiance users are not immunocompromised, but many patients prescribed the drug for heart failure or CKD are in the 50+ age group where Shingrix is routine.

Empagliflozin and Alcohol: Clinical Considerations

Drinking alcohol on Jardiance requires caution, though it is not an absolute contraindication. Two overlapping risks emerge from the combination.

Volume Depletion and Dehydration

Empagliflozin causes osmotic diuresis by excreting glucose. Alcohol is independently diuretic through suppression of antidiuretic hormone (ADH). The combination can produce additive volume depletion, raising the risk of dizziness, orthostatic hypotension, and acute kidney injury in susceptible patients.

In EMPA-REG OUTCOME, volume depletion events (hypotension, dehydration, hypovolemia) occurred in 2.4% of patients on empagliflozin 10 mg vs. 1.3% on placebo [4]. Adding regular alcohol consumption to this baseline risk compounds the effect.

Euglycemic DKA Risk

Empagliflozin carries an FDA black-box-adjacent warning for diabetic ketoacidosis (DKA), which can occur even when blood glucose is below 250 mg/dL (euglycemic DKA). The FDA drug safety communication on SGLT2 inhibitors and DKA notes that fasting, low-carbohydrate diets, and alcohol use are precipitating factors [9].

Alcohol suppresses hepatic gluconeogenesis and glycogenolysis. In a patient already relying on osmotic glucose excretion from empagliflozin, heavy drinking may trigger ketone accumulation. Patients should limit alcohol to moderate intake (one drink per day for women, two for men) and avoid drinking on an empty stomach.

Practical Guidance for Patients

Patients should stay well-hydrated when drinking. Skipping empagliflozin on days of anticipated heavy alcohol intake is sometimes recommended by prescribers, but this decision requires individual discussion, not a blanket protocol. Patients with a history of DKA, frequent binge drinking, or low-carbohydrate diets warrant explicit counseling.

Other Clinically Significant Jardiance Drug Interactions

The FDA label identifies a small number of pharmacodynamic interactions worth reviewing alongside the vaccine and alcohol discussion [1].

Diuretics

Co-administration with loop or thiazide diuretics amplifies volume depletion and the risk of hypotension. The Jardiance prescribing information recommends monitoring volume status and electrolytes when initiating the drug in patients already on diuretics [1]. This is particularly relevant in heart failure patients, where Jardiance is now approved based on data from the EMPEROR-Reduced trial (N=3,730), which showed a 25% reduction in the composite of cardiovascular death or hospitalization for heart failure (HR 0.75, 95% CI 0.65 to 0.86, P<0.001) [10].

Insulin and Insulin Secretagogues

Adding empagliflozin to insulin or sulfonylureas increases hypoglycemia risk. The prescribing information recommends a lower dose of insulin or the secretagogue when empagliflozin is added [1]. This interaction has direct implications for vaccination visits: a hypoglycemic episode during or after vaccination could complicate post-vaccine monitoring.

Positive UGT Inducers

Rifampin, a potent UGT1A3 and UGT2B7 inducer, reduces empagliflozin exposure by approximately 35% based on pharmacokinetic modeling in the label. Clinicians should be aware of this if patients are co-prescribed rifampin for tuberculosis treatment [1].

How Diabetes Affects Vaccine Immunogenicity: The Broader Context

Diabetes-associated immune changes are the main clinical reason to ensure patients on empagliflozin are fully vaccinated, even though the drug itself does not impair immune responses.

Mechanisms of Immune Impairment in Diabetes

Chronic hyperglycemia impairs neutrophil chemotaxis, phagocytosis, and oxidative burst capacity. A review in Nature Reviews Immunology described how advanced glycation end-products (AGEs) interfere with pattern recognition receptor signaling [11]. Empagliflozin's glucose-lowering effect may actually partially restore immune function by reducing hyperglycemia-driven glycation. This is a plausible but not yet proven benefit in terms of vaccine immunogenicity.

HbA1c and Vaccine Response

A 2020 study in Diabetes Care (N=3,979) found that adults with type 2 diabetes and HbA1c above 9% had significantly lower seroprotection rates to influenza vaccine compared to those with HbA1c below 7% [12]. Empagliflozin, by reducing HbA1c by approximately 0.5 to 0.8% at the 10 mg dose in placebo-controlled trials, may indirectly support better vaccine responses in patients who achieve glycemic targets [1].

A Practical Decision Framework for Vaccination in Empagliflozin-Treated Patients

Clinicians can use the following logic at each patient encounter:

1. Check for active symptomatic infection (UTI, genital mycotic infection). If present and febrile, defer non-urgent vaccines and treat the infection first.
2. Confirm volume status. Patients who appear dehydrated from osmotic diuresis should receive fluids and return when stable for vaccines requiring post-injection monitoring periods.
3. Review the full ACIP adult schedule, filtered by the patient's age, comorbidities (CKD, heart failure, diabetes), and prior vaccination history.
4. No dose adjustments to vaccines or to empagliflozin are needed around routine vaccination.
5. Document vaccination status in the same chart review as the HbA1c, eGFR, and UACR, since all are ongoing monitoring priorities for SGLT2 inhibitor users.

Empagliflozin in Chronic Kidney Disease: Vaccination Implications

The FDA expanded Jardiance's indication to reduce eGFR decline, end-stage kidney disease, cardiovascular death, and hospitalization for heart failure in adults with CKD in 2023, based on the EMPA-KIDNEY trial (N=6,609) [13]. CKD itself modifies vaccine recommendations in two important ways.

First, patients with eGFR <30 mL/min/1.73m² have reduced antibody responses to hepatitis B vaccine and may require higher-dose formulations or additional doses. Second, CKD patients qualify for all pneumococcal and influenza vaccine recommendations that apply to immunocompromised patients [5].

Empagliflozin is not recommended to be initiated in patients with eGFR <20 mL/min/1.73m² for glycemic control [1]. For its heart failure and CKD indications, the drug may be continued at lower eGFR values with appropriate monitoring. Clinicians managing these patients should coordinate with nephrology on vaccine schedules specific to CKD staging.

Live Vaccines: Is There Any Specific Concern?

Live attenuated vaccines (MMR, varicella, yellow fever, LAIV intranasal influenza) require a functional immune system to produce immunity without causing disease. Because empagliflozin is not immunosuppressive, it poses no known contraindication to live vaccines [1][5].

This is a meaningful clinical distinction. Patients on high-dose corticosteroids, TNF-alpha inhibitors, or JAK inhibitors generally cannot receive live vaccines. Patients on Jardiance face no such restriction.

Clinicians should still screen for other concurrent medications. A patient on Jardiance who is also taking prednisone at doses above 20 mg/day for more than two weeks should not receive live vaccines, but that restriction comes from the prednisone, not the empagliflozin.

Monitoring Parameters During Vaccination Visits

Standard pre-vaccination screening does not change for patients on empagliflozin. But a few observations are worth building into clinical workflow.

Blood pressure screening before vaccine administration is standard in many practices. Empagliflozin reduces systolic blood pressure by approximately 3 to 5 mmHg in clinical trials [1]. Patients presenting with lower-than-expected blood pressure at a vaccine visit may have compounding factors (diuretics, alcohol, low oral intake) worth addressing before injection.

Renal function and electrolytes do not require same-day testing for routine vaccine visits, but the annual monitoring schedule for eGFR and potassium in SGLT2 inhibitor users should not be deprioritized. The 2024 ADA Standards of Care recommend at least annual eGFR and urine albumin-to-creatinine ratio (UACR) monitoring in all patients with diabetes [6].